Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TENUATE vs TENUATE DOSPAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.
Releases norepinephrine from nerve terminals in the lateral hypothalamic feeding center, reducing appetite.
FDA-approved: short-term (up to 12 weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with exogenous obesity.,Off-label: long-term management of obesity (not FDA-approved for extended use).
Short-term adjunct in exogenous obesity,FDA-approved for obesity management
25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.
25 mg orally three times a day, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.
4-6 hours (terminal); clinical context: short half-life supports multiple daily dosing
The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function, though clinical effects may last longer due to tissue distribution.
Extensively metabolized in the liver via N-dealkylation to active metabolites (ethylaminopropiophenone and diethylaminopropiophenone). Enzymes involved include CYP3A4 and CYP2D6.
Hepatic via CYP3A4 and other CYP enzymes
Renal (90% as metabolites, ~10% unchanged); minor biliary/fecal (<10%)
Renal excretion of unchanged drug and metabolites; approximately 85-90% of the dose is excreted in urine within 48 hours, with less than 5% in feces.
~92% (primarily albumin)
Approximately 20-30% bound to plasma proteins.
~4 L/kg (extensive tissue distribution, including CNS)
Approximately 5-10 L/kg, indicating extensive tissue distribution.
Oral: ~60-70% (first-pass metabolism)
Rapidly absorbed from the gastrointestinal tract; absolute oral bioavailability is about 10-20% due to extensive first-pass hepatic metabolism.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-59 m L/min), use with caution and consider dose reduction.
Contraindicated in Child-Pugh Class C; use with caution in Class A and B, consider dose reduction.
Contraindicated in severe hepatic impairment. For Child-Pugh A or B, use with caution and consider reducing dose to 12.5 mg twice daily.
Not recommended for children under 16 years of age.
Not recommended for use in children under 12 years. For adolescents 12-17 years, same adult dosing may be used under strict supervision.
Initial dose at 12.5 mg twice daily; titrate slowly due to increased sensitivity and risk of adverse effects.
Initiate at lower dose (12.5 mg twice daily) due to increased sensitivity and risk of adverse effects. Maximum dose 75 mg per day.
There is no FDA boxed warning for Tenuate.
None
Primary pulmonary hypertension: rare but serious condition associated with use.,Cardiac valvulopathy: risk increases with prolonged use or combination with other serotonergic drugs.,Tachyphylaxis: tolerance to anorectic effects may develop within a few weeks.,Psychiatric effects: may exacerbate psychiatric disorders, particularly in patients with history of substance abuse.,Seizures: risk increased in patients with epilepsy or history of seizures.
Pulmonary hypertension,Valvular heart disease,Seizures,Psychiatric disturbances,Tolerance and dependence,May impair ability to drive or operate machinery
Hypersensitivity to diethylpropion or other sympathomimetic amines.,Advanced arteriosclerosis, cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma.,History of drug abuse, agitated states.,Concurrent use (or within 14 days of discontinuing) MAO inhibitors (hypertensive crisis risk).
Advanced arteriosclerosis,Cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,During or within 14 days of MAOI therapy
Avoid caffeine and other stimulants (e.g., in coffee, tea, cola, energy drinks) as they may increase cardiovascular side effects. Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if also taking MAOIs, but this is relevant only if transitioning therapy. No specific food restrictions otherwise, but a reduced-calorie diet is essential for efficacy.
No specific food interactions. However, avoid excessive caffeine intake as it may increase stimulant effects. Take with or without food; high-fat meals may delay absorption.
First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal growth and neonatal withdrawal symptoms (tremors, hypertonia, feeding difficulties). Avoid use unless clearly needed.
FDA Pregnancy Category X: Teratogenic effects demonstrated in animal studies; contraindicated in pregnant women due to increased risk of fetal malformations, particularly in the first trimester. Potential for neonatal withdrawal symptoms (hyperexcitability, feeding disorders) with third trimester exposure.
Excreted in human milk; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., irritability, poor weight gain). Use caution; decision to discontinue nursing or drug based on importance to mother.
Excretion in human milk unknown; risk of serious adverse reactions in nursing infants (e.g., CNS stimulation, growth suppression). Use during breastfeeding contraindicated. M/P ratio not established.
No specific pharmacokinetic data; however, pregnancy may alter metabolism. Start with lowest effective dose (25 mg BID) and monitor clinical response. Avoid sustained-release formulations due to altered GI transit.
No dose adjustment possible; drug contraindicated entirely during pregnancy due to known teratogenicity. If pregnancy occurs, discontinue immediately and manage with alternative therapy.
Tenuate (diethylpropion) is a sympathomimetic amine anorectic indicated for short-term (8-12 weeks) adjunct in obesity management. Avoid in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, or glaucoma. Monitor blood pressure and heart rate regularly. Tolerance may develop; discontinue if tolerance occurs. Contraindicated with MAOIs or within 14 days of their use. May impair ability to drive or operate machinery.
TENUATE DOSPAN (diethylpropion) is a schedule IV controlled substance used as an adjunct in obesity management. Avoid concurrent use with MAOIs due to hypertensive crisis risk. Monitor for tachyphylaxis and potential for abuse; limit use to short-term (up to 12 weeks). Contraindicated in patients with hyperthyroidism, glaucoma, or history of drug abuse.
Take exactly as prescribed; do not increase dose or duration.,May cause dizziness or blurred vision; avoid driving if affected.,Inform your doctor if you have heart disease, high blood pressure, or thyroid problems.,Avoid alcohol and other CNS stimulants while taking this medication.,Report any chest pain, palpitations, or severe headache immediately.,Do not take with other appetite suppressants without consulting your doctor.,This medication is only for short-term use; combine with diet and exercise.
Take exactly as prescribed; do not increase dose or frequency.,Do not crush or chew the controlled-release tablet; swallow whole.,Report any chest pain, palpitations, or shortness of breath immediately.,Avoid alcohol and other CNS stimulants.,Use caution when driving or operating machinery until you know how this drug affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TENUATE vs TENUATE DOSPAN, answered by our medical review team.
TENUATE is a Sympathomimetic anorectic that works by Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.. TENUATE DOSPAN is a Sympathomimetic anorectic that works by Releases norepinephrine from nerve terminals in the lateral hypothalamic feeding center, reducing appetite.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TENUATE and TENUATE DOSPAN depend on the specific clinical indication. These are both Sympathomimetic anorectic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TENUATE is: 25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.. The standard adult dose of TENUATE DOSPAN is: 25 mg orally three times a day, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TENUATE and TENUATE DOSPAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TENUATE is classified as Category C. First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal. TENUATE DOSPAN is classified as Category C. FDA Pregnancy Category X: Teratogenic effects demonstrated in animal studies; contraindicated in pregnant women due to increased risk of fetal malformations, particularly in the fi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.